The FDA’s withdrawal of its authorization for Evusheld, a monoclonal antibody therapy used to prevent and treat Covid-19, leaves no monoclonals available for this purpose. Another monoclonal, ...

A recent study co-authored by a Warren Alpert Medical School professor showed the effectiveness of convalescent plasma therapies for treating COVID-19 early in its disease course and preventing ...

Researchers from the Johns Hopkins Bloomberg School of Public Health supported the first blood center in the U.S. to be granted full FDA approval to provide convalescent plasma to immunocompromised ...

Johns Hopkins Medicine researchers report that a prospective study of 14 infants and children demonstrated that convalescent plasma—a blood product collected from patients recovered from infections ...

Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...

Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of convalescent ...

Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients ...